Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT https://t.co/dShyBF4WST

• Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Met…
• https://x.com/RichardPAConway/status/1858220056968126725/photo/1

When you stop 🛑 #TCZ #tocilizumab at 6 months of #Rx in #PMR RELAPSES are V high DON’T stop #Toci in PMR too Early Rapid and frequent flares #ACR24 @RheumNow @ACRheum #1698 https://t.co/IX5EJOcIY5

• https://x.com/Janetbirdope/status/1858221372205617199/photo/1

This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx

• https://x.com/Janetbirdope/status/1858215259355382099/photo/1

Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR

• https://x.com/Dr_Brian_MD/status/1858215429992517954/photo/1

Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj

• Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide w…
• https://x.com/RichardPAConway/status/1858216031858078047/photo/1

Safer and less relapses in #Takayasu’s #arteritis In #MTX + #MMF Vs #Cyclo ➡️ #azathioprine @RheumNow #ACRBest @ACRheum abst#1696 WOW 😮 Amazing! https://t.co/y3BDjdAa6P

• https://twitter.com/janetbirdope/status/1858215259355382099

Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL

• https://x.com/DrMiniDey/status/1858218295322665117/photo/1

A#1691 Biomarkers for Rx response SSc ILD? 92 SSc-ILD pts, 19 had progressive pulm fibrosis (PPF) KL-6 - incr in PPF, decr in those w/o PPF CXCL-4 decr across cohort - non-signif trend for more w/o PPF Specifically in MMF: CRP, KL6, CXCL4 are predictive #ACR24 @RheumNow https://t.co/9fG6atcLmK

• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1

#Methotrexate is a dud in #PMR for benefit above #glucocorticoids ! #RCT MTX25mg/wk + Pred 15 Mg/d tapered to 0 at 1 yr vs #Prednisone + placebo same taper NO BENEFIT from #MTX #1697 #ACR24 @ACRheum @RheumNow As FYI Poster at #EULAR observed #Leflunomide better than #MTX https://t.co/RepBmOKIsA

• https://x.com/Janetbirdope/status/1858218884286804011/photo/1
• https://x.com/Janetbirdope/status/1858218884286804011/photo/1

#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544